JO3524B1 - مستحضرات قَابِلة للحَقْنِ - Google Patents

مستحضرات قَابِلة للحَقْنِ

Info

Publication number
JO3524B1
JO3524B1 JOP/2013/0115A JOP20130115A JO3524B1 JO 3524 B1 JO3524 B1 JO 3524B1 JO P20130115 A JOP20130115 A JO P20130115A JO 3524 B1 JO3524 B1 JO 3524B1
Authority
JO
Jordan
Prior art keywords
quinolin
thiophen
piperazin
benzo
butoxy
Prior art date
Application number
JOP/2013/0115A
Other languages
English (en)
Inventor
Sato Tetsuya
Hoshika Yusuke
Minowa Takuya
Toyofuku Hidekazu
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49483139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3524(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of JO3524B1 publication Critical patent/JO3524B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بتقديم مستحضر قابل للحقن يتميز بإطلاق معزز و الذي يكون في صورة قابلة للإعطاء كدواء بحيث يعطي تأثير </span>7<span dir="RTL">- </span>] 4<span dir="RTL">-(</span>4<span dir="RTL">-بنزو </span>[b]<span dir="RTL"> ثيوفين -</span>4<span dir="RTL">- يل- بيرازين-</span>1<span dir="RTL">-يل) بيوتكسي</span>[<span dir="RTL">-?</span>H<span dir="RTL">- كينولين-</span>2<span dir="RTL">-أون لفترة زمنية طويلة، يقوم المستحضر بإطلاق كمية فعالة علاجيا من </span>7<span dir="RTL">-</span>]4<span dir="RTL">-(</span>4<span dir="RTL">-بنزو</span>[b]<span dir="RTL"> ثيوفين</span><span dir="RTL">-</span>4<span dir="RTL">-يل-بيرازين-</span>1<span dir="RTL">-يل) بيوتكسي</span>[<span dir="RTL"> -</span>1H<span dir="RTL">- كينولين-</span>2<span dir="RTL">-أون لمدة أسبوع على الأقل. يقدم الاختراع الحالي مستحضرا قابلا للحقن يحتوي على </span>7<span dir="RTL">-</span>]4<span dir="RTL">-(</span>4<span dir="RTL">-بنزو</span> [b]<span dir="RTL">ثيوفين-</span>4<span dir="RTL">-يل-بيرازين-</span>1<span dir="RTL">-يل) بيوتوكسي</span>[<span dir="RTL"> -</span>1H<span dir="RTL">-كينولين-</span>2<span dir="RTL">-أون أو ملح من أملاحه كمكون فعال، و الذي يطلق المكون الفعال بطريقة تجعل من الممكن الحفاظ على تركيزه العلاجي الفعال في الدم لمدة أسبوع على الأقل</span>
JOP/2013/0115A 2012-04-23 2013-04-23 مستحضرات قَابِلة للحَقْنِ JO3524B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636932P 2012-04-23 2012-04-23
US201361791896P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
JO3524B1 true JO3524B1 (ar) 2020-07-05

Family

ID=49483139

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0115A JO3524B1 (ar) 2012-04-23 2013-04-23 مستحضرات قَابِلة للحَقْنِ

Country Status (32)

Country Link
US (5) US20150086632A1 (ar)
EP (1) EP2868318B2 (ar)
JP (1) JP6249944B2 (ar)
KR (1) KR102168263B1 (ar)
CN (4) CN104363912A (ar)
AR (1) AR090775A1 (ar)
AU (1) AU2013253518B2 (ar)
BR (1) BR112014026398B1 (ar)
CA (1) CA2871398C (ar)
CO (1) CO7151499A2 (ar)
CY (1) CY1123195T1 (ar)
DK (1) DK2868318T4 (ar)
EA (1) EA026124B1 (ar)
ES (1) ES2727454T5 (ar)
HK (1) HK1205678A1 (ar)
HR (1) HRP20190841T4 (ar)
HU (1) HUE043686T2 (ar)
IL (1) IL235211A0 (ar)
IN (1) IN2014DN08870A (ar)
JO (1) JO3524B1 (ar)
LT (1) LT2868318T (ar)
MX (1) MX361722B (ar)
MY (1) MY169099A (ar)
NZ (1) NZ630255A (ar)
PH (1) PH12014502366A1 (ar)
PL (1) PL2868318T5 (ar)
PT (1) PT2868318T (ar)
SG (2) SG11201406775UA (ar)
SI (1) SI2868318T2 (ar)
TW (1) TWI641395B (ar)
UA (1) UA118084C2 (ar)
WO (1) WO2013161830A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
WO2017106641A1 (en) * 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
US20200093821A1 (en) 2016-08-16 2020-03-26 Hexal Ag Pharmaceutical Compositions of a Benzothiophene Compound
EP3577111A1 (en) * 2017-02-02 2019-12-11 Hexal Aktiengesellschaft Crystalline brexpiprazole
JP7043156B2 (ja) * 2019-03-28 2022-03-29 大塚製薬株式会社 ベンゾアゼピン化合物含有凍結乾燥組成物
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
WO2023036003A1 (zh) 2021-09-07 2023-03-16 四川科伦药物研究院有限公司 注射用布瑞哌唑长效制剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274634B1 (en) 1997-05-14 2001-08-14 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030195179A1 (en) 2000-08-25 2003-10-16 Shirou Sawa Aqueous suspension preparations
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
ZA200602347B (en) * 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
EP2279727A3 (en) * 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
TW200808375A (en) 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
UA97286C2 (ru) 2007-07-31 2012-01-25 Оцука Фармасьютикал Ко., Лтд. Способ изготовления суспензии арипипразола и лиофилизированного состава
RU2481842C2 (ru) * 2008-03-11 2013-05-20 Алькон Рисерч, Лтд. Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
BRPI0922041A8 (pt) * 2008-11-19 2022-08-16 Merial Ltd Formulações compreendendo ceftiofur e cetoprofeno ou cetiofur e álcool benzílico.
MY174552A (en) * 2010-08-24 2020-04-24 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
US9469630B2 (en) * 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
RU2627469C2 (ru) * 2011-03-18 2017-08-08 Алкермес Фарма Айэленд Лимитед Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбита
JP2012232958A (ja) 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
NZ630428A (en) * 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Also Published As

Publication number Publication date
TWI641395B (zh) 2018-11-21
PH12014502366B1 (en) 2015-01-12
CA2871398A1 (en) 2013-10-31
PL2868318T5 (pl) 2022-06-20
SI2868318T2 (sl) 2022-04-29
IL235211A0 (en) 2014-12-31
CO7151499A2 (es) 2014-12-29
SI2868318T1 (sl) 2019-06-28
BR112014026398B1 (pt) 2022-11-29
EP2868318A1 (en) 2015-05-06
UA118084C2 (uk) 2018-11-26
AU2013253518B2 (en) 2017-10-05
HRP20190841T4 (hr) 2022-03-04
ES2727454T3 (es) 2019-10-16
US20200163960A1 (en) 2020-05-28
TW201406401A (zh) 2014-02-16
HUE043686T2 (hu) 2019-09-30
WO2013161830A1 (ja) 2013-10-31
KR102168263B1 (ko) 2020-10-21
PT2868318T (pt) 2019-06-07
US20180092910A1 (en) 2018-04-05
SG10201608684QA (en) 2016-12-29
MX2014012734A (es) 2015-04-10
EA201491937A1 (ru) 2015-03-31
HK1205678A1 (en) 2015-12-24
DK2868318T4 (da) 2022-03-28
IN2014DN08870A (ar) 2015-05-22
EP2868318A4 (en) 2015-12-09
ES2727454T5 (es) 2022-05-13
CA2871398C (en) 2021-04-27
US20150086632A1 (en) 2015-03-26
EP2868318B1 (en) 2019-03-06
LT2868318T (lt) 2019-07-25
JP6249944B2 (ja) 2017-12-20
PL2868318T3 (pl) 2019-09-30
US20240277702A1 (en) 2024-08-22
SG11201406775UA (en) 2014-12-30
EP2868318B2 (en) 2022-01-26
KR20150003336A (ko) 2015-01-08
PH12014502366A1 (en) 2015-01-12
MX361722B (es) 2018-12-14
US10624889B2 (en) 2020-04-21
CN107536802A (zh) 2018-01-05
EA026124B1 (ru) 2017-03-31
CN111888329A (zh) 2020-11-06
JPWO2013161830A1 (ja) 2015-12-24
CN110638752A (zh) 2020-01-03
BR112014026398A2 (pt) 2017-06-27
AU2013253518A1 (en) 2014-11-06
NZ630255A (en) 2016-05-27
DK2868318T3 (da) 2019-06-03
HRP20190841T1 (hr) 2019-07-26
MY169099A (en) 2019-02-18
CY1123195T1 (el) 2021-10-29
CN104363912A (zh) 2015-02-18
US20220305007A1 (en) 2022-09-29
AR090775A1 (es) 2014-12-03

Similar Documents

Publication Publication Date Title
JO3524B1 (ar) مستحضرات قَابِلة للحَقْنِ
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
PH12019501937A1 (en) Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
TR201904614T4 (tr) Novel pyrazole derivative.
PH12016500420A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112014015568A2 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
EP2886112A4 (en) COMPOSITION CONTAINING AS ACTIVE INGREDIENT OF S-ALLYL-L-CYSTEINE FOR PREVENTING OR TREATING OCULAR DISEASES, AND PHARMACEUTICAL FORMULATION COMPRISING THE SAME
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
HK1216253A1 (zh) 新型化合物、其藥學上可接受的鹽或光學異構體、用於製備它們的方法以及包含它們作為有效成分的用於預防或治療病毒性疾病的藥物組合物
EP2862573A4 (en) COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF VASER SPERMABILITY-RELATED DISEASES WITH IMATINIB OR PHARMACEUTICAL ACCEPTABLE SALT AS AN ACTIVE SUBSTANCE
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
IN2014DN10683A (ar)
IN2014DE00700A (ar)
TR201105424A2 (tr) Çinko etken maddeli bir farmasötik formülasyon.
IN2013CH01615A (ar)
GR1007907B (el) Φαρμακευτικο σκευασμα περιεχον ενα φαινοκαρβαμικο αναστολεα της ακετυλχοληνεστερασης